{"id":"aclatonium","rwe":[{"pmid":"28967201","year":"2019","title":"Effect of combined solifenacin and aclatonium in preventing dry mouth in patients with overactive bladder.","finding":"","journal":"Lower urinary tract symptoms","studyType":"Clinical Study"},{"pmid":"12701010","year":"2003","title":"Food residue at endoscopy in patients who have previously undergone distal gastrectomy: risk factors and patient preparation.","finding":"","journal":"Endoscopy","studyType":"Clinical Study"},{"pmid":"1696381","year":"1990","title":"Action of a new cholinergic agonist, aclatonium napadisilate, on isolated rat pancreatic acini.","finding":"","journal":"Pancreas","studyType":"Clinical Study"},{"pmid":"2255123","year":"1990","title":"[The effects of various gastrokinetic drugs on gastric emptying].","finding":"","journal":"Nihon Heikatsukin Gakkai zasshi","studyType":"Clinical Study"},{"pmid":"2476520","year":"1989","title":"The effect of a new synthetic cholinergic compound (aclatonium napadisilate) on interdigestive motility and pancreatic function in humans.","finding":"","journal":"International journal of pancreatology : official journal of the International Association of Pancreatology","studyType":"Clinical Study"}],"tags":[{"label":"aclatonium","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Muscarinic acetylcholine receptor","category":"target"},{"label":"CHRM1","category":"gene"},{"label":"CHRM2","category":"gene"},{"label":"CHRM3","category":"gene"},{"label":"Active","category":"status"},{"label":"Biliary dyskinesia","category":"indication"},{"label":"Chronic gastritis","category":"indication"}],"phase":"phase_2","safety":{"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"abovis","offLabel":[],"synonyms":["aclatonium","aclatonium napadisilate","abovis"],"timeline":[],"brandName":"Abovis","ecosystem":[{"indication":"Biliary dyskinesia","otherDrugs":[],"globalPrevalence":null},{"indication":"Chronic gastritis","otherDrugs":[],"globalPrevalence":159000000}],"mechanism":{"target":"Muscarinic acetylcholine receptor","targets":[{"gene":"CHRM1","source":"DrugCentral","target":"Muscarinic acetylcholine receptor","protein":"Muscarinic acetylcholine receptor M1"},{"gene":"CHRM2","source":"DrugCentral","target":"Muscarinic acetylcholine receptor","protein":"Muscarinic acetylcholine receptor M2"},{"gene":"CHRM3","source":"DrugCentral","target":"Muscarinic acetylcholine receptor","protein":"Muscarinic acetylcholine receptor M3"},{"gene":"CHRM4","source":"DrugCentral","target":"Muscarinic acetylcholine receptor","protein":"Muscarinic acetylcholine receptor M4"},{"gene":"CHRM5","source":"DrugCentral","target":"Muscarinic acetylcholine receptor","protein":"Muscarinic acetylcholine receptor M5"}],"modality":"Small Molecule","drugClass":"aclatonium","explanation":"Imagine your body's nervous system as a complex network of messengers. Abovis helps to regulate the flow of these messengers, specifically targeting the muscarinic acetylcholine receptor to treat conditions like biliary dyskinesia and chronic gastritis.","oneSentence":"Abovis works by binding to the muscarinic acetylcholine receptor, a protein that plays a key role in regulating various bodily functions.","technicalDetail":"Abovis acts as a competitive antagonist at the M3 muscarinic acetylcholine receptor subtype, inhibiting the parasympathetic nervous system's effects on smooth muscle contraction and glandular secretion."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/81","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ACLATONIUM","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:25:38.097998","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:49:11.248047+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"methanthelinium","drugSlug":"methanthelinium","fdaApproval":"1951-07-03","relationship":"same-target"}],"genericName":"aclatonium","indications":{"approved":[{"name":"Biliary dyskinesia","source":"DrugCentral","snomedId":197432008,"regulator":"FDA"},{"name":"Chronic gastritis","source":"DrugCentral","snomedId":8493009,"regulator":"FDA","globalPrevalence":159000000,"prevalenceMethod":"ai-extracted","prevalenceSource":"Microb Pathog, 2022 (PMID:35405277)"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"methanthelinium","brandName":"methanthelinium","genericName":"methanthelinium","approvalYear":"1951","relationship":"same-target"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"UC6I41G62N","CHEBI":"CHEBI:134901","INN_ID":"4832","UMLSCUI":"C2986959","ChEMBL_ID":"CHEMBL2110902","KEGG_DRUG":"D01955","PUBCHEM_CID":"2009","SECONDARY_CAS_RN":"55077-30-0"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":9,"therapeuticAreas":["Dermatology"],"biosimilarFilings":[],"recentPublications":[{"date":"2019 Jan","pmid":"28967201","title":"Effect of combined solifenacin and aclatonium in preventing dry mouth in patients with overactive bladder.","journal":"Lower urinary tract symptoms"},{"date":"2003 May","pmid":"12701010","title":"Food residue at endoscopy in patients who have previously undergone distal gastrectomy: risk factors and patient preparation.","journal":"Endoscopy"},{"date":"1990 Jul","pmid":"1696381","title":"Action of a new cholinergic agonist, aclatonium napadisilate, on isolated rat pancreatic acini.","journal":"Pancreas"},{"date":"1990 Feb","pmid":"2255123","title":"[The effects of various gastrokinetic drugs on gastric emptying].","journal":"Nihon Heikatsukin Gakkai zasshi"},{"date":"1989 Oct","pmid":"2476520","title":"The effect of a new synthetic cholinergic compound (aclatonium napadisilate) on interdigestive motility and pancreatic function in humans.","journal":"International journal of pancreatology : official journal of the International Association of Pancreatology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Abovis (ACLATONIUM) is a small molecule drug that targets the muscarinic acetylcholine receptor. It is used to treat biliary dyskinesia and chronic gastritis. The commercial status of Abovis is currently unknown, and it is not clear if it is patented or available as a generic medication. As a pharma professional, it is essential to consider the potential safety implications of Abovis, including its mechanism of action and potential side effects. Further research is needed to fully understand the properties and clinical applications of Abovis.","enrichmentLevel":5,"visitCount":0,"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:49:11.248047+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":false,"score":2}}